Challenge and unlock the full value of your oncology innovation !
MATWIN is an accelerator program aiming at maximizing innovation transfer potential exclusively on oncology. Through a support course over 3 or 6 months, candidates will have access to support through expertise, coaching/mentoring and a qualified network of partners likely to help them accelerate the development of their project.
The program is open to European candidates (academic team or start-up) developing an innovative R&D product or service in oncology. Candidates from Switzerland, UK and Norway can apply.
Consult different support paths’ details below.
You can also access MATWIN’s expertise throughout the year (see “Tailor-made service offers” section)
Usual process (6 months)
application possible until October 31, 2023 at the latest; application file to be completed (downloadable below)
1/ Submit application
2/ Preselection pitch
3/ Written International Board’s review
4/ 2 personalized coaching sessions
5/MATWIN International Board interview
Fast-track process (3 months)
application possible until February 28, 2023; submit your presentation (5 slides max) with audio support
1/ Preselection pitch by MATWIN’s Board
2/ 1 personalized coaching session
3/ MATWIN International Board interview
Before applying, please read the MATWIN charter listing the rights and obligations of MATWIN and candidates
To apply
Consult the FAQs in the text of the call for applications.
Before submitting any application, it is essential to contact MATWIN to jointly assess the opportunity.
Eligibility requirements
- Innovative R&D project (service offers (e.g. CRO services) will be automatically discarded)
- Original and innovative target, MoA, marker/biomarker, technological approach
- Strength of intellectual property (patent application filed or pending)
- Maturity: if product: established preclinical in vivo (or early clinical) POC, MoA, SAR, associated biomarker if diagnostic test: selectivity, specificity, impact on the therapeutic choice...
Program advantages
- Become familiar with market expectations by accessing the expertise of an international network of peers, pharmas / biotechs / investors
- Optimize the industrial structuring of the project and enhance its development potential
- Obtain development plan validation guidelines (clinical positioning, indications, milestones, etc.)
- Become investor-ready while reducing their go-to-market risk
- Increase the project’s, visibility and accelerate its promotion for the benefit of patients